Pancreatic, Neuroendocrine GI, and Adrenal Cancers

June 1, 2016
Al B. Benson III, MD, FACP

,
Jeffrey R. Olsen, MD

,
Aaron R. Sasson, MD

This management guide covers the risk factors, symptoms, diagnosis, staging, and treatment of pancreatic cancer, pancreatic cystic neoplasms, pancreatic endocrine tumors (PETs), carcinoid tumors of the GI tract, adrenocortical carcinoma, and pheochromocytoma.

Pancreatic Cancer

Pancreatic cancer is the fourth leading cause of cancer death in the United States. In 2016, an estimated 53,070 new cases will be diagnosed, with 41,780 deaths. It is estimated that by 2020, pancreas cancer will be the second leading cause of cancer deaths in the United States.

Incidence and Epidemiology

Gender

The incidence of pancreatic cancer is slightly higher in men than in women. These gender differences are most prominent among younger individuals.

Age

The peak incidence of pancreatic carcinoma occurs in the seventh decade of life. Two-thirds of new cases occur in people > 65 years of age. Recently, several epidemiologic studies have demonstrated worrisome projections regarding pancreatic cancer: an analysis of the Surveillance, Epidemiology and End Results (SEER) database has projected a marked increase in the number of cancer cases in the next 20 years, which is attributed in part to the increasing number of adults over the age of 65. The authors estimated that there will be a 55% increase in the number of pancreatic cancer cases over the next 20 years.

Race

The incidence of pancreatic cancer in the US is higher in the black population, with an excess risk of 40% to 50% over that of whites, and a higher incidence among black males compared with black females. Perhaps more importantly, black males probably have the highest risk of pancreatic cancer worldwide.

Survival

Cancer of the pancreas is a highly lethal disease, with ductal adenocarcinoma being the most common histologic type. The overall 5-year survival has not improved in the past 30 years and remains < 5%. Median survival is approximately 6 months for patients with metastatic disease and 10 months for patients with locally advanced disease. Approximately 50% of patients with pancreatic adenocarcinoma present with clinically apparent metastatic disease, and only a minority (10% to 20%) of patients are considered resectable. There have been some increases in 5-year survival following a curative resection (21% to 25%), potentially due to increased referral to higher-volume teaching institutions; however, 50% of patients die of recurrent tumor within 2 years.

In the past, surgical resection has been associated with high morbidity and mortality. In the last 20 years, however, there have been marked improvements in outcomes following resection. Several single-institution series have reported mortality rates of < 3% following resection. Factors that appear to be important in predicting long-term survival following resection include clear surgical margins, small tumor size (< 2 cm), negative lymph nodes, and reduced perioperative morbidity.

Etiology and Risk Factors

The specific risk factors for pancreatic cancer are not as striking as those for other gastrointestinal (GI) malignancies, such as esophageal and gastric carcinomas. There does, however, appear to be a significant relationship between pancreatic cancer and environmental carcinogens.

Cigarette smoking

Cigarette smoke is one of the carcinogens directly linked to pancreatic malignancies. Heavy cigarette smokers have at least a twofold greater risk for pancreatic carcinoma than nonsmokers. In Japan, cigarette smoking carries an even greater risk, which can be as much as 10-fold in men smoking one to two packs of cigarettes daily.

N-nitroso compounds

These compounds, found particularly in processed meat products, reliably induce pancreatic cancer in a variety of laboratory animals. However, no study has directly linked dietary carcinogens to pancreatic cancers in humans. A recent report evaluated the association between dietary nitrate and nitrite intake and pancreatic cancer risk in the National Institute of Health (NIH)-AARP Diet and Health Study. This study showed modest evidence that processed meat sources of dietary nitrate and nitrite may be associated with pancreatic cancer among men only.

Caffeine

The contribution of caffeine consumption to the development of pancreatic carcinoma is controversial. One case-controlled study showed a correlation between caffeine consumption and pancreatic cancer. However, most other studies including a meta-analysis have been equivocal.

Alcohol

There has been no clear-cut relationship shown between alcohol use and pancreatic carcinoma.

Diabetes

Hyperglycemia does not seem to be a risk factor for pancreatic cancer. However, 10% of all patients are found to have new-onset diabetes mellitus with the diagnosis of pancreatic carcinoma.

Obesity

A report by the American Institute for Cancer Research (AICR) and the World Cancer Research Fund (WCRF) estimated that 28% of pancreatic cancers can be attributable to obesity. As the obesity problem in the United States worsens, this percentage may continue to increase (as described in the WCRF/AICR report, Policy and Action for Cancer Prevention, 2009). Furthermore, recent data suggest that obesity may influence survival in pancreatic cancer, with obese patients having a reduced survival compared with non-obese patients.

Genetic factors

More than 80% of resected pancreatic cancers have been found to harbor activating point mutations in the oncogene KRAS. In addition, the tumor-suppressor genes pl6, CDKN2A, TP53, SMAD4, and DPC4 are frequently inactivated in this cancer. Research is also focusing on aberrantly methylated genes in pancreatic cancer using methylation-specific polymerase chain reaction and the identification of microRNAs as targets for detection strategies.

It is estimated that hereditary factors, due to germline mutations, may account for 5% of pancreatic cases. Familial pancreatic carcinoma has been associated with the following genetic syndromes: hereditary pancreatitis, ataxia-telangiectasia, hereditary nonpolyposis colorectal cancer, familial atypical mole melanoma syndrome, Peutz-Jeghers syndrome, and familial breast cancer. Patients with BRCA 1 and BRCA 2 mutations are at increased risk for developing pancreatic cancer, and these individuals may respond to platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors. Families with CDKN2A germline mutations may be at higher risk of developing pancreatic cancer than those without these mutations.

In 2012, the International Cancer of the Pancreas Screening (CAPS) Consortium released consensus guidelines on screening for pancreatic cancer. This multidisciplinary panel of 49 experts recommended against routine screening in the general population, but did recommend screening with endoscopic ultrasound (EUS) and/or magnetic resonance imaging (MRI)/magnetic resonance cholangiopancreatography (MRCP) for the following high-risk groups: those with at least two blood relatives and at least one first-degree relative with pancreatic cancer; individuals who are carriers of p16, PALB2, or BRCA2 mutations plus a first-degree relative with pancreatic cancer; those with Peutz-Jeghers syndrome; and those with Lynch syndrome plus a first degree relative with pancreatic cancer.

Signs and Symptoms

The initial clinical features of pancreatic carcinoma include anorexia, weight loss, abdominal discomfort or pain, and new-onset diabetes mellitus or thrombophlebitis. The vague nature of these complaints may delay diagnosis for several months.

Pain

Specific symptoms usually relate to localized invasion of peripancreatic structures. The most common symptom is back pain, which stems from tumor invasion of the splanchnic plexus and retroperitoneum or pancreatitis. This pain is described as severe, gnawing, and radiating to the middle of the back. Pain can also be epigastric or in the right upper quadrant if bile duct obstruction is present.

Jaundice

In a majority of cases, when tumors involved the head of the pancreas, patients also present with jaundice. Painless or sometimes painful jaundice occurs when lesions involve the intrapancreatic bile duct.

GI symptoms

Tumor invasion of the duodenum or gastric outlet may give rise to nausea or vomiting as a presenting symptom. This symptom is rare early in the course of the disease. Changes in bowel habits related to pancreatic insufficiency may also be present, along with associated steatorrhea.

Glucose intolerance

Recent onset of glucose intolerance associated with GI symptoms in elderly patients should alert physicians to the possibility of pancreatic carcinoma.

Palpable gallbladder

When it occurs without cholecystitis or cholangitis, a palpable gallbladder suggests malignant obstruction of the common bile duct until proved otherwise. This so-called Courvoisier’s sign is present in about 25% of patients with pancreatic cancer.

Other physical findings. Other physical findings include Trousseau’s syndrome (migratory superficial phlebitis), ascites, Virchow’s node (left supraclavicular lymph node), or a periumbilical mass (Sister Mary Joseph’s node).

Screening and Diagnosis

Early diagnosis of pancreatic carcinoma is difficult, but essential if surgical resection and cure are to be improved. Defining early lesions at a resectable stage remains a diagnostic challenge. To date, leading medical organizations have not recommended routine screening of asymptomatic individuals for pancreatic cancer.

Serum markers

The use of serologic tumor markers, such as CA19-9, for pancreatic carcinoma was originally thought to be appropriate as a screening tool. However, since the prevalence of pancreatic carcinoma in the general population is extremely low (0.01%), many false-positive screening results are generated. Also, the sensitivity of CA19-9 is not high (20%) in stage I cancers. Nevertheless, CA19-9 may be a useful marker for diagnosing patients at high risk who have appropriate symptoms; such individuals include smokers, recent-onset diabetics, those with familial pancreatic cancer, or those with unexplained weight loss or diarrhea. This marker correlates with tumor burden and is useful in following disease and in assessing the adequacy of resection or therapy. CA19-9 should be interpreted with caution in patients who have biliary obstruction or jaundice, because it is falsely elevated in such patients. Furthermore, 5% to 15% of the population are unable to synthesize CA19-9; in such patients, levels of this marker would be falsely low, even in the presence of extensive tumor burden.

Laparoscopy

This diagnostic tool is useful for staging patients with pancreatic carcinoma and for formulating treatment plans. Approximately 10% to 15% of patients considered to have resectable disease are found to have distant metastases at laparoscopy. The false-negative rate of laparoscopy is < 10%. The strongest indications for laparoscopy are patients with borderline resectable disease who are being considered for resection and tumors of the body and tail of the pancreas.

Imaging techniques

Imaging for pancreatic carcinoma is best performed with conventional ultrasonography and CT.

Ultrasonography. The limit of sonographic resolution for early pancreatic carcinoma is a diameter of 1 to 1.5 cm. A mass located in the pancreatic head will produce dilatation of the common bile duct and pancreatic duct. The actual sensitivity of ultrasonography in the diagnosis of pancreatic carcinoma is about 70%.

CT. This diagnostic tool provides better definition of the tumor and surrounding structures than does ultrasonography. CT scan is also operator-independent. CT correctly predicts unresectable tumors in 85% of patients and resectable tumors in 70% of patients. Findings of tumor unresectability on CT scanning include distant lymphadenopathy, encasement or occlusion of the superior mesenteric artery (SMA) or celiac artery, occlusion of the portal vein or superior mesenteric vein (SMV), and distant metastases. Multiphasic CT scan with thin slices throughout the pancreas increases the accuracy of detecting pancreatic carcinoma in general and vessel involvement in particular. This technique permits rapid data acquisition and computer-generated 3D images of the mesenteric arterial and venous tributaries on many planes. CT is quicker and less expensive than angiography and uses less contrast medium.

PET. The use of positron emission tomography (PET) with 18fluorodeoxyglucose (FDG) in the evaluation of patients with pancreatic cancer has been proposed for evaluation of the primary tumor and detection of distant metastases. A 2001 study of 126 patients with focal, malignant, or benign pancreatic lesions showed high sensitivity of FDG-PET for detection of small pancreatic neoplasms. Lack of focal glucose uptake excludes pancreatic neoplasms (sensitivity, 85.4%; specificity, 60.9%). Although potentially useful in selected clinical scenarios, routine application of FDG-PET for pancreatic cancer staging is not recommended by consensus groups, including the National Comprehensive Cancer Network (NCCN).

MRI. MRI is considered equivalent to pancreatic protocol CT imaging for the initial evaluation of pancreatic cancer by consensus groups, including the NCCN.

EUS. In a comparison of EUS and spiral CT, both techniques showed comparable efficacy in detecting tumor involvement of lymph nodes and the SMVs and portal veins. However, EUS is less helpful in the evaluation of the SMA. EUS is also valuable in obtaining tissue confirmation of the pancreatic mass and suspicious lymph nodes before starting treatment for unresectable or borderline resectable lesions.

Recently, some investigators have expressed interest in using EUS to screen high-risk patients, individuals with defined genetic syndromes, and those with a strong family history of pancreatic cancer for evidence of the disease. In a recent study of 78 high-risk patients, screening showed neoplastic changes in 10% of the subjects. However, the challenge of EUS is the current inability to detect malignant precursor lesions, known as PanIN (pancreatic intraepithelial neoplasia).

Endoscopic retrograde cholangiopancreatography (ERCP). While this technique was considered essential in the past, it is rarely required for diagnostic purposes following EUS and magnetic resonance cholangiopancreatography (MRCP) to define the extent of disease and ductal involvement. For patients that present with jaundice and the CT scan reveals dilatation of the common bile duct without an obvious mass, ERCP may be complementary to spiral CT. For tumors that obstruct the common bile duct, ERCP may be required for stent placement to alleviate biliary obstruction. ERCP findings of pancreatic cancer include an abrupt or tapered cutoff of either or both the main pancreatic and common bile ducts. Complications of bile and pancreatic duct manipulation include infection and pancreatitis. These risks must be carefully weighed against the added value of ERCP in a completely imaged patient.

Pathology

Adenocarcinoma

This type of tumor, arising from the exocrine gland ductal system, is the most common type of pancreatic cancer, accounting for 95% of all cases. Two-thirds of these cancers originate in the pancreatic head; the remainder arise in the body or tail. Most ductal carcinomas are mucin-producing tumors and usually are associated with a dense desmoplastic reaction.

Although most pancreatic adenocarcinomas arise from the ductal epithelium, pancreatic acinar carcinomas and cancers arising from mucinous cystic neoplasms are also found.

Multicentricity. Multicentricity, which is usually microscopic, is not unusual.

TABLE 1: TNM staging of pancreatic tumors

FIGURE 1: Actuarial survival as a function of regional lymph node status in patients with pancreatic cancer.

Metastatic spread. Perineural invasion occurs in the majority of patients with pancreatic carcinoma. In addition, pancreatitis distal to and surrounding the tumor is usually present. Most patients present with lymph node metastases in the region of the pancreaticoduodenal drainage basins. The subpyloric and inferior pancreatic head, SMA, and para-aortic lymph node groups also may be involved. Distant metastatic spread most commonly involves the liver and peritoneal surfaces.

Staging and Prognosis

Pancreatic adenocarcinoma is staged according to local spread of disease, nodal status, and distant metastatic involvement using the American Joint Committee on Cancer (AJCC) TNM system (Table 1). The tumor (T) staging of the primary tumor includes an analysis of direct extension of disease to the duodenum, bile duct, or peripancreatic tissues. A T4 advanced cancer may extend directly to the SMA or celiac axis, meaning that the cancer is unresectable.

Independent prognostic factors

Lymph node metastases and tumor size and differentiation have independent prognostic values in patients with pancreatic carcinoma. Significantly improved survival is seen in patients with smaller lesions, lymph node-negative tumors, and tumors in which the surgical margins are not involved.

Lymph node and margin status

Prior to the era of adjuvant therapy, lymph node status was the most dominant prognostic factor (Figure 1). It is now rivaled by surgical margin status in series where surgical margins have been meticulously examined.

Treatment of Pancreatic Cancer

Surgical treatment of resectable disease

The rate of resection for curative intent ranges from 10% to more than 75%, with the higher percentage resulting from both a more aggressive approach and better preoperative staging for resectability. Also, there is growing evidence that patients with potentially resectable pancreatic cancer have a shorter hospital stay, reduced surgical mortality, and an overall better outcome if the surgery is performed at “high-volume” medical centers staffed by surgeons who treat approximately 16 or more operable cases per year.

Extended resections may include portal or superior mesenteric vessels, the colon, the adrenal glands, or the stomach. If resection of adjacent organs or tissues results in the conversion of a positive to a negative resection margin, it may be of benefit to the patient. With regard to the extent of lymph node dissection, several recent, prospective, randomized studies have shown an increase in postoperative morbidity, but with no improvement in overall survival in patients undergoing an extended lymph node dissection.

Currently, pancreatic lesions may be classified as resectable, borderline resectable, and unresectable. The definition of borderline resectable tumors includes impingement or abutment on the SMV/portal vein, short segment venous occlusion with a suitable proximal and distal vein for reconstruction, minimal involvement of the gastroduodenal and hepatic artery, and < 180° involvement of the SMA. Criteria for unresectability include detection of distant metastases and circumferential involvement of the SMA, hepatic, or celiac artery.

Determination of resectability. The initial approach to surgery for pancreatic carcinoma includes a determination of resectability. This determination should be first made preoperatively with high-quality CT or MRI and, perhaps EUS, although EUS is not as reliable as the other modalities for assessing vascular involvement. Operative determination of resectability includes careful examination of the liver, porta hepatis, and portal and superior mesenteric vessels. The head of the pancreas and uncinate process are mobilized by an extensive Kocher maneuver to evaluate the head of the pancreas. The SMA is palpated, and its relationship to the tumor is assessed. The hepatic artery and celiac trunk are examined to make certain there is no vascular encasement.

Operative intervention.

• Laparoscopy-Laparoscopic examination of the abdominal cavity has the ability to detect occult metastatic disease to the peritoneum and liver, which occurs in 5% to 10% of patients with cancers in the head of the pancreas. Most surgeons take a selective approach, and use laparoscopy for patients with high-risk features; high levels of CA19-9, vascular involvement, excess weight loss, or back pain. Patients with cancer involving the body and tail of the pancreas, should undergo laparoscopy due a higher incidence of detecting occult metastatic disease (20% to 40%).

• Intraoperative biopsy-Most patients with resectable pancreatic tumors can successfully undergo pancreaticoduodenectomy without an intraoperative biopsy. A time-consuming frozen section interpretation may not be informative, and histologic confirmation may be impossible with small lesions associated with peritumoral pancreatitis. Most large series of pancreaticoduodenectomy for carcinoma include resections of benign pathology, based on clinical judgment. A negative fine-needle cytology should not deter an experienced surgeon from proceeding with resection. In patients without a histologic diagnosis, however, a biopsy is warranted in patients considered unresectable at the time of attempted resection.

• Whipple vs pylorus-preserving procedure-If the tumor is deemed to be resectable, a standard pancreaticoduodenectomy (Whipple procedure) or pylorus-preserving Whipple (PPW) procedure is performed. The PPW option theoretically eliminates the nutritional problems caused by a reduced gastric reservoir and gastric dumping, but has not been shown to alter long-term nutritional status. If there is any doubt about cancer proximity or blood supply to the pylorus, an antrectomy should be performed. If the tumor approaches the pylorus or involves the subpyloric nodes, classic antrectomy is recommended. Recent prospective randomized studies have shown that there is no significant difference in clinical or oncologic outcomes between pylorus-preserving and standard Whipple resection.

• Reconstruction technique-The most common reconstruction technique after a Whipple resection utilizes the proximal jejunum in an antecolic or retrocolic position to complete the pancreaticojejunostomy, which is followed by a choledochojejunostomy or hepaticojejunostomy and gastrojejunostomy or duodenojejunostomy. Pancreaticogastrostomy is also an effective and safe means of creating the anastomosis.

• Postoperative complications-Analysis of national databases indicate that the average post-operative mortality rate following pancreaticoduodenectomy is 6% to 8%, however studies from high-volume centers report a mortality rate of < 2%.

The leading causes of postoperative mortality include postoperative sepsis, hemorrhage, and cardiovascular events. Most of the septic complications arise from pancreaticojejunostomy leaks.

Delayed gastric emptying and leak or fistula from the pancreatic anastomosis are the leading causes of postoperative morbidity. Today, with appropriate drainage and nutritional support, more than 95% of pancreatic fistulas will heal using conservative measures.

An analysis of 200 patients who underwent resection of pancreatic adenocarcinoma in the era prior to adjuvant therapy found that the most important factors influencing long-term survival were the diameter of the primary tumor, status of the resected lymph nodes, and status of the resected margins. Patients with tumors < 3 cm in diameter had significantly longer median survival and 5-year survival rates (21 months and 28%, respectively) than those with tumors < 5% for those with positive nodes. Patients with no lymph node involvement had a 5-year survival rate of 36%, as compared with < 5% for those with positive nodes. Patients who underwent resections with negative margins had a 5-year survival rate of 26%, vs 8% for those with positive margins. The type of resection (pylorus-preserving vs standard Whipple procedure) did not influence survival.

• Body and tail tumors-Tumors in the body and tail of the pancreas are typically larger than tumors in the head of the pancreas and are often metastatic on presentation. For patients who are surgical candidates, resection employs a distal pancreatectomy with concomitant splenectomy. Because of the large size of these tumors, removal may require resection of adjacent organs. Of note, the rate of pancreatic leaks following distal pancreatectomy is approximately 30% to 40%, although, with appropriate treatment, they resolve using conservative measures.

Surgical palliation

Surgical palliation is also considered in patients undergoing exploration with curative intent. Jaundice, gastric obstruction, and pain may be alleviated by surgical palliation.

Biliary tract obstruction. Either a choledochojejunostomy or cholecystojejunostomy can be used to bypass the biliary obstruction. Recurrent jaundice and cholangitis are less likely to develop when the common duct is used for decompression. Nonoperative means of biliary decompression can often be accomplished with endoscopically placed expandable metallic stents. The use of metal stents should be reserved for patients who have been fully evaluated and deemed unresectable by a multidisciplinary team.

Duodenal obstruction. Although duodenal obstruction is rare as a presenting symptom, duodenal involvement may occur eventually in 25% of patients. Some investigators believe that prophylactic bypasses are safe and should be performed in all patients. One phase III trial supports prophylactic bypass, but the subject remains controversial.

Pain relief. Severe back pain may be an incapacitating symptom. Pain relief may be achieved by alcohol injection of the celiac plexus, which may be performed intraoperatively, percutaneously, or endoscopically. An intraoperative injection of 25 mL of ethanol (95%) on both sides of the celiac axis will assuage tumor pain. (For further discussion of these techniques, see the “Pain Management” chapter.)

Neoadjuvant and adjuvant therapies

Radiation therapy.

• Preoperative chemoradiation therapy-Several single-institution studies have evaluated the role of preoperative irradiation in conjunction with fluorouracil (5-FU)- or gemcitabine-based chemotherapy. In these studies, 60% to 80% of the lesions were completely resected 1 to 1.5 months after the completion of chemoradiotherapy. Median survival has ranged from 16 to 36 months, but no phase III trials have been conducted to evaluate preoperative therapy vs postoperative sequencing.

The appropriate radiation dose and volume are dependent on the planned concurrent chemotherapy. For patients undergoing concurrent 5-FU–based neoadjuvant chemoradiation, doses of 4,500 to 5,000 cGy are appropriate with inclusion of both the primary tumor and elective nodal coverage. Although interest in concurrent gemcitabine-based approaches was initially tempered by high rates of GI toxicity, treatment with full-dose gemcitabine (eg, 1,000 mg/m2) appears to be well tolerated when radiation treatment volumes are limited to the primary tumor and omit elective nodal coverage. There are research initiatives to further address the role of neoadjuvant chemotherapy. For example, the recent data demonstrating the high response rate from the FOLFIRINOX regimen (5-FU, leucovorin, irinotecan, and oxaliplatin) in metastatic pancreatic cancer are of interest to determine if this combination will enhance resectability when used in the neoadjuvant setting, and are the subject of a new NCI GI Intergroup study of FOLFIRINOX followed by chemoradiation and surgery.

This study is based on a randomized phase III trial in metastatic disease by Conroy et al which included 342 patients and compared the combination chemotherapy regimen of 5-FU, irinotecan, leucovorin, and oxaliplatin (FOLFIRINOX) to standard gemcitabine, showing significant improvement in response rates (31.8% vs 11.3%, P < .001), progression-free survival (6.4 months vs 3.3 months, P < .001), and survival (11.1 months vs 6.8 months, P < .001). This regimen is best reserved for patients with good performance, given the potential toxicity.

• Postoperative chemoradiation therapy-The role of radiotherapy in the adjuvant setting has been called into question by several European trials. Criticism of these studies includes lack of quality control and suboptimal chemotherapy and radiotherapy schedules in the arms that included radiotherapy. In addition, for most GI sites, the preferred sequencing of modalities has been to give several months of full-dose multidrug chemotherapy before proceeding to radiotherapy with concurrent chemotherapy, a sequencing that was not used in the European trials.

A recently activated clinical trial being conducted by the European Organisation for Research and Treatment of Cancer (EORTC), Radiation Therapy Oncology Group (RTOG), and the Southwestern Oncology Group (SWOG) addresses all of these criticisms. Postoperative care for patients with cancer of the pancreatic head will be double-randomized, with all patients receiving six cycles of gemcitabine. The first randomization will be to receive or not receive concurrent erlotinib with gemcitabine. (The erlotinib randomization has been discontinued, and all patients will receive gemcitabine alone). The second randomization will be whether to administer either one further cycle of gemcitabine or radiotherapy (50.4 Gy/28 fractions) with concurrent infusional fluorouracil or equivalent capecitabine (Xeloda). All radiotherapy treatment plans will be centrally reviewed in advance of treatment. Thus, this trial is evaluating the contribution of postoperative radiotherapy using standard-of-care techniques with proactive quality control.

The American College of Surgeons Oncology Group (ACOSOG) Z05031 trial was a phase II trial that tested a regimen of radiation therapy, cisplatin, interferon-alfa, and 5-FU in patients with resected pancreatic cancer. The trial demonstrated a median survival of 27.1 months, which was the longest survival reported with use of adjuvant therapy in a cooperative group trial. However, use of this regimen was associated with significant toxicity, and only 56% of patients completed the entire treatment course.

In addition, the GI Intergroup completed a randomized phase II trial to explore new combinations incorporating the monoclonal antibodies bevacizumab (Avastin) and cetuximab (Erbitux), each given with gemcitabine; irradiation was given with oral capecitabine. The results suggest no added benefit with the addition of either bevacizumab or cetuximab. A recent meta-analysis of 15 prospective randomized trials showed that adjuvant chemotherapy significantly improved disease-free survival, overall survival, and 2-year survival, however chemoradiation did not. Given the variability of radiotherapy quality assurance in these trials, the currently open RTOG 0848 trial described above may better define the role of adjuvant chemoradiation.

Postoperative chemotherapy. A German randomized phase III trial including 368 patients with resected pancreatic cancer compared postoperative gemcitabine given for 6 months vs observation. Disease-free survival was significantly greater for patients receiving postoperative gemcitabine (13.4 months vs 6.9 months; P < .001), including for patients with either R0 or R1 resection. Overall survival, however, was initially not significantly different between the gemcitabine and control groups (22.1 months vs 20.2 months; P = .06). In an updated analysis, the benefits of gemcitabine as compared with observation remained. Despite an improvement in median survival of only 2 months noted among treated patients (22.8 months vs 20.2 months; P = .005), a 5-year survival of 21% in the treatment arm vs 9% in the observation arm was reported.

The European Study Group for Pancreatic Cancer (ESPAC)-3 was a multicenter randomized phase III trial which compared adjuvant fluorouracil vs gemcitabine following resection of pancreatic cancer. Following R0/R1 resection, patients were randomized to 5-FU (425 mg/m2) bolus on days 1-5 every 28 days vs gemcitabine (1,000 mg/m2) given intravenously on days 1, 8, and 15 every 4 weeks. Both regimens were continued for 6 months. A total of 1,088 randomized patients were enrolled after a minimum follow-up of 2 years, median survival for the 5-FU/leucovorin group was 23 months, compared with 23.6 months for the gemcitabine group. There was no statistical difference between the two study arms.

A trial of gemcitabine plus nab-paclitaxel vs gemcitabine following pancreas resection has been initiated.

Borderline resectable lesions. These lesions comprise 10% to 15% of patients presenting to physicians. Data from phase II preoperative chemoradiotherapy trials indicate that trimodal therapy is crucial for margin-free resection and long-term survival. An analysis from the ESPAC-1 trial showed that chemotherapy alone is ineffective for patients who have had resection for microscopic disease at a margin (R1), thus adding further support for both chemotherapy and radiation therapy for these borderline resectable patients. As mentioned, the NCI GI Intergroup is conducting a study of FOLFIRINOX followed by chemoradiation followed by surgery for borderline resectable patients.

Sidebar: The Alliance trial A021101 (NCI ClinicalTrials.gov identifier: NCT01821612) investigated the tolerability and efficacy of neoadjuvant FOLFIRINOX with standard of care chemoradiation (50.4 Gy and capecitabine 825 mg/m2 twice daily) and postoperative gemcitabine (100 mg/m2 on days 1, 8, and 15 × 2 cycles) in 22 patients with borderline resectable pancreatic cancer. Results were reported at the 2015 meeting of ASCO. All 22 patients completed treatment with FOLFIRINOX, and 95% completed chemoradiation therapy. A total of 15 patients (68%) underwent planned resection. (Among the remaining 8 patients, 7 had disease progression and 1 refused surgery.) Responses by RECIST during preoperative therapy were as follows: there were 2 complete responses (CRs), 4 partial response (PRs), 15 patients with stable disease, and 1 patient with progressive disease (PD). The R0/R1 resection rate was 68%, and 9% of these patients had a pathologic CR. Among the 15 patients who underwent resection, 14 (93%) were R0. During neoadjuvant therapy, the rate of grade III events was 46% and of grade IV events was 5%; no patients experienced toxicity during chemoradiation. The authors concluded that while a response by RECIST was uncommon, the high rates of R0 resection and pathologic response observed suggest efficacy of this preoperative regimen (Katz MHG et al: J Clin Oncol 33[suppl]: abstract 4008, 2015).

Treatment of unresectable lesions

Radiation Therapy. Radiation therapy can prolong and/or improve quality of life in some patients with unresectable adenocarcinoma of the pancreas. Conventionally fractionated radiation is better combined with chemotherapy. Long-term survival is, unfortunately, highly unusual. Stereotactic body radiation therapy (SBRT) is an emerging radiation technique for pancreatic cancer which delivers higher radiation doses over a short period of time (typically, five treatments) to a focused treatment volume typically consisting of the primary tumor alone. Emerging phase I/II data suggest greater local efficacy for SBRT compared with conventionally fractionated radiotherapy, although this technique remains investigational for pancreatic cancer.

Chemoradiation. The addition of chemotherapy to radiation therapy has been shown to improve the survival of patients with unresectable pancreatic adenocarcinoma. In a Gastrointestinal Tumor Study Group (GITSG) trial of unresectable disease conducted in the 1970s, moderate-dose radiation (4,000 cGy) with 5-FU chemotherapy significantly improved survival, as compared with higher doses of radiation (6,000 cGy) and no chemotherapy (median survival, 9.6 vs 5.2 months). Given the study era, radiotherapy was administered using two dimensional split-course techniques. GITSG has also compared chemotherapy plus irradiation with chemotherapy alone and demonstrated a significant improvement with combined-modality therapy (median survival, 42 vs 32 weeks).

A systematic review of 11 trials including 794 patients with locally advanced pancreatic cancer using radiation/combined-modality therapy showed a survival benefit for chemoradiation over irradiation alone, but there was no significant advantage for chemoradiation followed by chemotherapy compared with chemotherapy alone.

The Eastern Cooperative Oncology Group (ECOG) conducted a randomized, prospective trial in patients with locally advanced, unresectable, nonmetastatic pancreatic adenocarcinoma. Patients were randomized to receive either gemcitabine monotherapy or radiation therapy, given concurrently with and followed by gemcitabine. The overall survival was 11.1 months in the combination-therapy group and 9.2 months in the chemotherapy-only group (P = .034). Despite the statistical significance of these findings, this trial was plagued by poor accrual and was terminated early.

Based on these data, many practitioners would favor several months of gemcitabine-based chemotherapy before proceeding to chemoradiotherapy. This allows early delivery of optimal chemotherapy and spares the patient destined to rapid dissemination of disease from the morbidity associated with use of concurrent chemoradiotherapy. If radiotherapy is given concurrently with 5-FU, elective nodal doses of 4,500 cGy and primary tumor doses of 5,400 cGy based on bowel tolerance are appropriate. In all cases, delineation of the target volume should incorporate all available diagnostic imaging. Image-guided radiation therapy (IGRT) is appropriate to ensure patient setup and daily target visualization.

• Approaches under investigation-Since local-only failure remains a significant contributor to death for patients with locally advanced disease, further investigations of novel chemoradiotherapy techniques, including radiosensitization, are under way. Additional areas of active investigation include selection of patients at greatest risk of local failure based on genomic factors, including Smad4.

Objective response by size criteria is difficult to achieve with radiotherapy. This may be due to the substantial sclerotic component associated with pancreatic adenocarcinomas rather than true radiation resistance. Regardless, until it becomes possible to achieve a high incidence of objective clinical responses, it will be difficult to persuade surgeons to attempt resections after chemoradiotherapy for unequivocal clinical T4 lesions. Recent results reported from the University of Michigan and Rush University Medical Center are of particular interest in this regard. The Michigan group has a long interest in concurrent radiotherapy and gemcitabine because of the drug’s radiosensitizing properties. Previous work from the group suggested that normal tissue tolerance limits the ability to give full doses of both radiotherapy and gemcitabine concurrently. However, in their most recent work, these investigators have taken advantage of technical developments in radiation oncology by using IMRT, breath-holding techniques to limit respiratory excursion, and online daily setup verification to treat macroscopic disease with tight planning target volumes. Radiation doses were successfully escalated to 5,500 cGy in 25 fractions over 5 weeks with gemcitabine (1,000 mg/m2 over 100 minutes) given on weeks 1, 2, 4, and 5. Objective responses were seen in 52% of 27 cases, with a mean overall survival of 23 months, including two cases converted to resectable status with minimal residual disease at surgery.

The dose of gemcitabine that can be given concurrently with irradiation depends on the volume and dose of radiation. If full doses of gemcitabine (1,000 mg/m2/wk) are given concurrently with irradiation, the volume of radiation must be markedly reduced to avoid unacceptable GI toxicity. In the Michigan series, the treatment volume included the primary tumor only plus a 1-cm planning target volume (PTV) margin, with omission of nodal coverage.

Treatment of metastatic adenocarcinoma

Pancreatic adenocarcinoma is still one of the most frustrating, resistant solid neoplasms to treat, and therapy for metastatic disease remains palliative. Few agents have demonstrated activity in > 10% of patients diagnosed with this disease.

Chemotherapy. Because metastatic pancreatic carcinoma is incurable, the anticipated risks of chemotherapy, which are often substantial, must be balanced against the gains that may be achieved; unfortunately, these are few. Patients who are debilitated due to their underlying or comorbid disease should not be offered chemotherapy, because their likelihood of deriving any benefit is exceedingly slim. However, patients who desire therapy and who, while symptomatic, still have good performance status may be offered “standard” chemotherapy (Table 2), or, if possible, they should be encouraged to participate in a clinical trial.

TABLE 2: Chemotherapy regimens for pancreatic cancer

• 5-FU-Historically, single-agent 5-FU has been associated with a response rate of up to 25% in pancreatic cancer. The use of 5-FU, doxorubicin, and mitomycin (FAM) and 5-FU plus doxorubicin offer no advantage over 5-FU alone. 5-FU plus leucovorin appears to be ineffective.

• Gemcitabine-Gemcitabine is indicated for the treatment of locally advanced or metastatic pancreatic adenocarcinoma. Gemcitabine was compared with 5-FU in a group of 126 previously untreated patients and showed a small, but statistically significant, improvement in response rate. Median survival in the gemcitabine group was 5.7 months, with 18% of patients alive at 12 months, as compared with 4.4 months in the group receiving 5-FU, with 2% of patients alive at 12 months. Perhaps more importantly, clinical benefit response (a composite measurement of pain, performance status, and weight) occurred in 23.8% of the gemcitabine-treated group vs 4.8% of the 5-FU–treated group. Due to its palliative potential, gemcitabine has been a standard of care for patients with unresectable, metastatic pancreatic adenocarcinoma; however, recent clinical trials with combination therapies have changed the standard of care for good-performance-status patients.

• Combination therapy-There have been a number of attempts to improve the therapeutic outcome for patients with metastatic pancreatic cancer by comparing promising combinations of agents in randomized clinical trials. Unfortunately, the results have been disappointing. The ECOG compared gemcitabine with or without 5-FU, demonstrating a median survival of 5.4 months for gemcitabine vs 6.7 months for the combination; however, this difference was not statistically significant. Another trial explored the addition of irinotecan to gemcitabine. There was no survival benefit when this regimen was compared with gemcitabine alone, although the combination did increase the tumor response rate (16.1% vs 4.4%; P < .001).

A meta-analysis of 15 randomized trials showed a significant survival benefit for patients with advanced pancreatic cancer and a good performance status who received gemcitabine either with a platinum analog (hazard ratio [HR] = 0.85; P = .01) or a fluoropyrimidine (HR = 0.9; P = .03).

A European randomized trial of 319 patients with advanced pancreatic cancer compared capecitabine plus gemcitabine vs gemcitabine alone and showed no difference in overall survival (8.4 vs 7.2 months; P = .234). The combination showed improved median overall survival in patients with good performance status (10.1 vs 7.4 months; P = .014).

Two recently reported combination regimens have significantly improved the outcome for patients with metastatic disease compared with gemcitabine alone. The randomized PRODIGE trial compared FOLFIRINOX vs gemcitabine for patients with good performance status and metastatic disease, demonstrating the most significant survival outcomes, favoring FOLFIRINOX, that have been observed for any previous combination. (median overall survival 11.1 months vs 6.8 months; P < .001). Quality of life was better for those receiving FOLFIRINOX despite increased toxicity. Since neutropenia is a significant risk, routine use of colony-stimulating growth factor is recommended and the regimen should be reserved for good performance status patients. The combination of nab-paclitaxel plus gemcitabine was superior to gemcitabine in the recently reported IMPACT randomized clinical trial (overall survival = 8.5 months vs 6.7 months; P < .001). The 1-year and 2-year survival, response rate, and progression-free survival also were improved with the combination, thus supporting the use of nab-paclitaxel plus gemcitabine as a standard of care.

A phase III study of 565 patients compared gemcitabine vs the combination of gemcitabine plus the multitargeted antifolate pemetrexed (Alimta), and demonstrated a significant response benefit with the combination (14.8% vs 7.1%; P = .004). However, overall and progression-free survival rates were comparable. There was increased hematologic toxicity with the combination.

Three Intergroup metastatic pancreatic cancer trials have been reported. ECOG completed a trial of gemcitabine vs fixed-rate infusion gemcitabine vs fixed-rate gemcitabine plus oxaliplatin, accruing 832 patients. At a median follow-up of 12.2 months, neither of the two investigational regimens was significantly better than standard gemcitabine (both groups had approximately 1 month longer median survival). Cancer and Leukemia Group B (CALGB) compared bevacizumab plus gemcitabine vs gemcitabine alone, and SWOG evaluated gemcitabine with or without cetuximab. These studies reported no difference in outcome with the addition of an antibody.

In a phase III trial, 607 patients with metastatic pancreatic cancer were given gemcitabine and erlotinib (Tarceva) with either bevacizumab or placebo. The results, published in 2009 by Van Cutsem et al, showed that patients receiving bevacizumab had significantly longer progression-free survival, but their improvement in overall survival was not significant. In the Charité Onkologie Clinical Studies in GI Cancer (CONKO) 003 trial, presented at the 2008 ASCO meeting, 168 patients who progressed after gemcitabine therapy received 5-FU and leucovorin with or without oxaliplatin (Eloxatin). The study demonstrated a significant advantage in progression-free survival favoring patients receiving oxaliplatin.

The NCIC has presented a randomized phase III study comparing gemcitabine with or without erlotinib in 530 patients with metastatic pancreatic cancer. The combination produced improvement in both overall (6.24 vs 5.91 months; HR = 0.82; P = .038) and progression-free survival (HR = 0.77; P = .007). As with other epidermal growth factor receptor-targeted agents, rash was associated with response. Diarrhea increased with the combination. Patients with BRCA1/2-associated pancreatic adenocarcinoma may respond to platinum-based chemotherapy. A recent database study evaluated BRCA1/2 patients treated with either platinum-based or non-platinum chemotherapy, with the results favoring platinum combinations (overall survival = 22 vs 9 months; P = .039). Patients with good performance status who progress after gemcitabine-based therapy may respond to second-line therapies including 5-FU, leucovorin, and oxaliplatin (FOLFOX), 5-FU, leucovorin, and irinotecan (FOLFIRI), and capecitabine, as noted in small studies. Several new therapeutic approaches recently have been reported. A total of 90 previously treated metastatic disease patients were randomized on a vaccine study of CyGVAX with or without live attenuated Listeria monocytogenes expressing mesothelin (CRS-207), favoring the combination (9.7 vs 4.6 months; HR = 0.53, P = .02). The phase III NAPOLI-1 study of MM-398 (irinotecan liposome injection) in combination with 5 FU and leucovorin vs 5FU and leucovorin showed improved survival with the triplet combination (6.1 vs 4.2 months without MM-398; HR = 0.67; P = .0122) for previously treated metastatic pancreatic cancer patients. The hypoxia-activated prodrug (HAP) TH-302 combined with gemcitabine vs gemcitabine alone was evaluated in a phase II trial of advanced pancreatic cancer demonstrating improved progression-free survival (5.6 vs 3.6 months; P = .005) and is being further evaluated in the phase III MAESTRO study.

• Novel approaches-A progressively better understanding of the molecular biology of pancreatic cancer has revealed numerous new therapeutic targets. Some agents currently being studied include vaccines, immunotherapy, PARP inhibitors (eg, BRCA2), mammalian target of rapamycin (mTOR) inhibitors, hedgehog pathway inhibitors, and inhibitors of multiple tyrosine kinases as examples.

Pancreatic Cystic Neoplasms

Pancreatic cystic neoplasms are made up of a variety of neoplasms with a wide range of malignant potential. These neoplasms are divided into serous cystadenomas, mucinous cystadenomas, and intraductal papillary mucinous neoplasms (IPMN). The latter two mucinous neoplasms carry a malignant potential. These cysts typically require differentiation from inflammatory pseudocysts. The correct diagnosis is paramount in order to institute appropriate therapy.

Differentiating these cystic neoplasms from a pseudocyst is often based on a patient’s prior history of pancreatitis and risk factors for pancreatitis. Radiographically, the stigmata of pancreatitis such as diffuse calcifications or inflammatory changes surrounding the pancreas may often help in distinguishing pseudocyst from a cystic neoplasm.

Distinguishing serous cystadenomas from mucinous neoplasms (mucinous adenomas or IPMN) is also important because serous cystadenomas do not have any significant malignant potential. Radiographically, serous cystadenomas occasionally have a starburst appearance with a centrally located scar; this scar is present in approximately 30% of the patients evaluated with a CT scan. Mucinous cystadenomas often typically have multiple cystic areas with intracystic septae and may occasionally have peripheral calcifications. Furthermore, they occur almost exclusively in females. IPMN are associated with a connection to the pancreatic duct either via endoscopic retrograde cholangiopancreatography or MRCP. This distinguishes IPMN from mucinous cystic neoplasms. IPMN can involve the main pancreatic duct or its branches.

Further evaluation of cystic neoplasms often includes endoscopic ultrasound with fine-needle aspiration. Analysis of cystic fluid can help in obtaining a correct diagnosis. Cyst fluid carcinoembryonic antigen (CEA) has been shown to be the most accurate for differentiating mucinous cystic neoplasms. Whereas a high CEA level (ie, > 182 ng/mL) is more indicative of a mucinous cystic neoplasm, a very low cystic fluid CEA (< 5 ng/mL) is more indicative of a serous cystadenoma.

Occasionally, it requires a combination of tests to help distinguish inflammatory pseudocysts from cystic neoplasm. A multidisciplinary approach incorporating gastroenterologists, surgeons, and radiologists is often required.

With regard to treatment, resection is typically indicated for symptomatic cystic neoplasms, as well as all mucinous cystadenomas (known as mucinous cystic neoplasm [MCN]). With regard to IPMNs, all IPMNs involving the main pancreatic duct should be resected. A more selective approach is utilized for IPMNs involving the pancreatic duct branches, such as an associated solid mass, an enhancing mural nodule, or associated main duct dilatation.

In April 2015, the American Gastroenterological Association (AGA) Institute issued a guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts, with the caveat that the recommendations are “conditional,” with “very low quality evidence.” Key suggestions from the guidelines are that: significant changes in the characteristics of the cyst, including the development of a solid component, increasing size of the pancreatic duct, and/or diameter ≥3 cm, are indications for EUS-FNA; surveillance of pancreatic cysts should be discontinued if there has been no significant change in cyst characteristics after 5 years of surveillance or if the patient is no longer a candidate for surgery; surgery should be performed on patients with both a solid component and a dilated pancreatic duct and/or concerning features identified by EUS and FNA, to reduce the risk of mortality from carcinoma; patients being considered for surgery on a pancreatic cyst should be referred to a center with demonstrated expertise in pancreatic surgery; and patients who have invasive cancer or dysplasia in a cyst that has been surgically resected should undergo MRI surveillance of any remaining pancreas every 2 years.

Pancreatic Endocrine Tumors

Pancreatic endocrine tumors (PETs) or pancreatic neuroendocrine tumors (PNETs) cover a spectrum of neoplasms. These tumors may produce clinical syndromes based on excessive hormone production (see below), or produce symptoms (abdominal pain, jaundice, etc) by mass effect in tumors that do not secrete hormones (nonfunctional tumors). With the increased use of CT scanning, there are a greater number of identified nonfunctioning neuroendocrine tumors of the pancreas.

PETs are not rare. Autopsy studies have documented an incidence of 1.5%. Most of these lesions are clinically silent.

Approximately 20% of patients with Zollinger-Ellison syndrome (ZES) develop PETs in the setting of multiple endocrine neoplasia type 1 (MEN-1). MEN-1 is inherited as an autosomal-dominant trait and is characterized by tumors of multiple endocrine organs, including the pituitary, pancreas, and parathyroid. The gene for MEN-1, which has been localized to the long arm of chromosome 11, has been identified and named MENIN.

The normal islet contains α, β, and γ cells, and enterochromaffin cells, which primarily secrete glucagon, insulin, somatostatin, and serotonin, respectively. All of these hormones may be secreted in excess by PETs. Other hormones that may be secreted by these tumors include vasoactive intestinal peptide (VIP), gastrin, pancreatic polypeptide (PP), and calcitonin. The aggressiveness of a PET in terms of its metastatic potential appears to be a factor of the cell of origin.

The natural history of PETs is highly variable. As noted, many remain asymptomatic and undiagnosed. Factors useful in predicting biologic behavior included mitotic activity (reported in 10 high-power fields) and Ki-67 (a marker of cellular proliferation). For example, tumors with poorly differentiated histology may be quite malignant and spread to distant organs and treatment of these tumors are similar to small-cell lung cancer.

Types of Tumors

Insulinomas

These are beta-cell tumors of the pancreatic islets that produce insulin. Four-fifths of insulinomas occur as a solitary lesion, and < 10% of these tumors demonstrate malignant potential (in terms of invasiveness or the development of metastases). In patients with the MEN-1 syndrome, insulinomas are multicentric (10% of patients). A small group of insulinomas is associated with diffuse islet-cell hyperplasia or nesidioblastosis.

Gastrinomas

These tumors are gastrin-secreting tumors associated with the ZES. They can be either sporadic or familial. Sporadic gastrinomas do not have associated endocrinopathies, whereas hereditary gastrinomas occur in patients with MEN-1 syndrome. Patients with the sporadic form of ZES may have single or multiple gastrinomas. This contrasts with the finding for patients with hereditary MEN-1 PETs, who generally have a more diffuse tumor process within the pancreas.

It is known that 80% to 90% of gastrinomas are located within the “gastrinoma triangle,” defined as the junction of (1) the cystic and common duct, (2) the second and third portions of the duodenum, and (3) the neck and body of the pancreas.

More than 90% of gastrinomas are malignant. The spectrum of clinical disease progression includes localized tumors, regional lymph node metastases, and widespread metastatic disease.

Other types

Approximately 75% of VIPomas and approximately 50% of all glucagonomas and somatostatinomas are malignant.

Nonfunctional tumors

Although many PETs cause considerable morbidity due to the inappropriately elevated levels of the hormones that they secrete, even “nonfunctional” PETs, such as those without an associated demonstrable hormone-related syndrome (ie, as PPomas, neurotensinomas, and nonsecretory PETs), may be aggressive. Nonfunctional tumors account for up to 70% of all PETs. Two-thirds of these nonfunctional tumors will demonstrate metastatic lesions at some point during the patient’s lifetime.

Signs and Symptoms

The symptom complex that is observed depends on which hormone or hormones are secreted in excess.

Insulinomas

These are associated with symptoms of recurrent hypoglycemia. Diagnosis of these tumors is made by the demonstration of inappropriately elevated levels of insulin, proinsulin, and C peptide at the time of hypoglycemia and an elevated insulin-glucose ratio of > 0.3).

Gastrinomas

Symptoms of gastrinoma-ZES are due to the effect of elevated levels of circulating gastrin. Ulceration of the upper GI tract is seen in > 90% of patients. Diarrhea is the second most common symptom. Approximately 25% of gastrinomas occur in the context of MEN-1 and are associated with parathyroid hyperplasia and hypercalcemia.

The diagnosis of ZES is established by the demonstration of hypergastrinemia (fasting serum gastrin concentration > 1,000 pg/mL) and gastric acid hypersecretion in a patient with ulcerative disease. Medications used for acid suppression could falsely elevate gastrin levels and should be discontinued before testing.

VIPomas

An excess of VIP causes a profuse, watery diarrhea, hypokalemia, hypophosphatemia, and hypochlorhydria, referred to as WDHA syndrome.

Glucagonomas

These tumors are associated with a rash (described as a necrotizing migratory erythema), glossitis, cheilosis, constipation and ileus, venous thrombosis, and diabetes.

Somatostatinomas

These tumors are rare and are associated with elevated blood glucose levels, achlorhydria, cholelithiasis, and diarrhea.

Tumor Localization

Insulinomas

Ultrasonography, CT, MRI, and selective arteriography with portal vein sampling have been utilized for the preoperative localization of insulinomas. The sensitivity of these preoperative imaging tests ranges from approximately 30% to 60%. This is because 40% of insulinomas measure 1 cm or less and two-thirds of these tumors are less than 1.5 cm.

Because of the limited success of preoperative localization tests, and because 90% of these tumors will be found and successfully resected by an experienced endocrine surgeon, there is a general trend toward performing fewer tests. Some centers utilize preoperative ultrasonography if the patient has not undergone prior pancreatic surgery. Other centers still routinely employ portal vein catheterization and angiography. Most centers with EUS availability use the modality as a standard diagnostic tool for these tumors.

More recently, intraoperative sonography has been shown to aid the surgeon. In one series, 84% of tumors not localized preoperatively were correctly located by surgical exploration and intraoperative sonography. Many lesions not discovered by surgical palpation may be found by this technique. At present, there is much less reliance on blind distal resection than was previously advocated. Obviously, the technique of intraoperative ultrasonography may not be as helpful for the MEN-1 syndrome, in which multiple small insulinomas are involved.

Gastrinomas

CT, ultrasonography, selective abdominal angiography, selective venous sampling of gastrin, intraoperative ultrasonography, EUS, and intraoperative endoscopy have all been reported to be useful in localizing gastrinomas. More recently, somatostatin receptor scintigraphy (SRS) has become a valuable tool for PET localization; several studies have suggested greater sensitivity and specificity with SRS than with other diagnostic tests.

Treatment

Surgery for insulinomas

Most small insulinomas can be treated with enucleation. For larger tumors or those in close proximity to the main pancreatic duct, a Whipple or distal pancreatectomy is preferable. If the insulinoma is not found at surgery, a blind pancreatectomy is not warranted. Further imaging and venous sampling studies may reveal the exact location of the tumor.

A surgical cure results in normal values on subsequent provocative testing, during which blood insulin and glucose concentrations are measured simultaneously. Some insulinoma recurrences actually represent persistent disease after incomplete tumor excisions or overlooked multiple secondary tumors.

Surgery for gastrinoma-ZES

The ideal treatment for gastrinoma-ZES is surgical excision of the gastrinoma. However, this approach is possible in only 20% of patients, most of whom have a sporadic tumor. With the development of effective antisecretory agents and preoperative localization with octreotide scanning, the majority of patients demonstrating widespread metastatic disease can be identified and spared surgical exploration. In addition, some series report that patients with nonmetastatic sporadic gastrinoma may have a higher incidence of extrapancreatic sites than was previously thought. One series has reported that two-thirds of gastrinomas are extrapancreatic.

Patients with sporadic gastrinoma. All patients with sporadic gastrinoma should undergo localization studies and be considered for exploratory laparotomy, with the goal of potential cure of ZES. Recent evidence suggests that resection of primary gastrinoma decreases the incidence of liver metastases and ZES. Overall, surgery produces complete remission in approximately 60% of patients with sporadic ZES, and subsequent survival is excellent.

Patients with ZES and MEN-1. Some experts believe that surgery should not be used in the management of patients with MEN-1 and ZES. Instead, they recommend treatment with antisecretory medications. This approach is somewhat controversial, because some authors believe that all patients without demonstrated liver metastases should undergo surgery to remove duodenal and pancreatic gastrinomas.

Moreover, since many patients with ZES and MEN-1 die of metastatic gastrinoma at a young age, a surgical approach may be warranted. Surgery should be performed only if imaging studies localize the tumor. Although radical surgery may not provide a cure, removal of large tumors may decrease metastatic potential and increase survival.

Surgical procedure for metastatic PNET. While an aggressive approach to the primary and surgical resection of liver metastases were initially controversial, this practice is acquiring more acceptability with reduction of morbidity and preservation of hepatic function; orthotopic liver transplantation remains controversial. However, several authors have demonstrated meaningful survival in patients with small, isolated lesions. The use of ablative procedures, with open, laparoscopic, or percutaneous techniques, can reduce the neurohormonal tumor burden, protect hepatic function, and provide palliation in patients with hormonal production.

Surgical resection for nonfunctioning tumors is indicated and should be performed with a goal of negative soft tissue and pancreatic margins. Due to the variable aggressive patterns of these tumors, there has been an interest in maximal debulking.

Radiation therapy for PNETs

Adjuvant therapy. There is no established role for adjuvant therapy after tumor resection of PETs. Anecdotal reports indicate that PETs may respond to palliative doses of irradiation. Long-term control of unresectable disease has been reported.

Chemotherapy for PNETs

PNETs are more sensitive to chemotherapy than are carcinoid tumors.

Single agents. Agents that have demonstrated antitumor activity include recombinant human interferon alfa-2a and alfa-2b (Roferon-A, Intron A, respectively), 5-FU, doxorubicin, dacarbazine, and streptozocin.

Two randomized placebo-controlled phase III trials for patients with advanced, lower-grade pancreatic neuroendocrine tumors have been reported. In the RADIANT-3 trial, everolimus (Afinitor) compared with placebo (Yao JC et al: N Engl J Med 2011) demonstrated superior progression-free survival (11 months vs 4.6 months, P < .001). Similarly, another randomized (Raymond E et al: N Engl J Med 2011) phase III trial of sunitinib (Sutent) compared with placebo for advanced pancreatic neuroendocrine tumors reported a significant improvement in progression-free survival favoring sunitinib (11.4 months vs 5.5 months, respectively; P < .0001).

RADIANT-4, a randomized phase III trial for patients with gastrointestinal and lung neuroendocrine tumors, compared everolimus plus best supportive care vs placebo plus best supportive care. The results, presented at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO) and in September 2015 at the European Cancer Congress, showed that the primary endpoint of progression-free survival was met favoring everolimus; investigators reported a 2.8-fold improvement in median progression-free survival, from 3.9 months to 11 months; P < .00001). A preplanned interim survival analysis showed a trend toward improved overall survival favoring everolimus (HR = 0.64; 95% CI, 0.40–1.05; P = 0.037), however this result did not achieve statistical significance.

The CLARINET trial recently reported the results of the somatostatin analogue lanreotide in low-grade (grade 1 and grade 2) pancreatic and intestinal neuroendocrine tumors (see carcinoid section). The trial demonstrated an improvement in progression-free survival for patients randomized to lanreotide, as compared with placebo.

Combination regimens. Combination chemotherapy is often more effective than monotherapy. For example, in an ECOG study involving the treatment of patients with PETs, the combination of 5-FU and streptozocin demonstrated a higher response rate than did streptozocin alone (63% vs 36%), as well as a better complete response rate (33% vs 12%) and median survival duration (26 vs 16.5 months). Therapy with doxorubicin plus streptozocin was superior to therapy with both 5-FU plus streptozocin and single-agent chlorozotocin in terms of response and survival and is the combination most widely used in the United States in PETs. Etoposide combined with cisplatin is active in poorly differentiated neuroendocrine malignancies but is marginally effective in well-differentiated lesions.

New agents. Antiangiogenic approaches and the recognition of other potential biologic targets have contributed to the development of a number of early-phase clinical trials incorporating bevacizumab with temozolomide (Temodar) and with FOLFOX chemotherapy, temozolomide with capecitabine, sorafenib (Nexavar), vatalanib, imatinib (Gleevec), thalidomide (Thalomid), and the mTOR inhibitors everolimus and temsirolimus (Torisel). Sunitinib and everolimus have been approved by the US Food and Drug Administration (FDA) for the treatment of pNETs based on randomized trials.

The CALGB 80701 (Alliance) randomized phase II trial of everolimus vs everolimus plus bevacizumab in 150 patients with locally advanced or metastatic pancreatic neuroendocrine tumors was reported at the ASCO 2015 annual meeting. Both progression-free survival (16.6 vs 14 months; HR = 0.80) and response rate (31% vs 12%; P = .005) favored the combination, although median survival was similar (36.7 vs 35 months). Adverse events were more frequent in the combination arm.

Treatment of symptoms

Octreotide. Octreotide (a somatostatin analog) can be used to control the symptoms from excess hormone production, particularly for VIP-producing tumors. A possible anti-proliferative effect of somatostatin analogs in pancreatic neuroendocrine tumors has recently been reported. As discussed more fully in the section on carcinoid tumors, a promising experimental approach for patients whose tumors express somatostatin receptors is the use of octreotide conjugated to a therapeutic radioisotope.

Other agents. Omeprazole (Prilosec), an inhibitor of the function of the parietal cell hydrogen pump, is more effective than histamine type 2 (H2)-receptor antagonists in blocking gastric acid production and is useful in the symptomatic management of gastrinomas.

Other agents available for symptomatic treatment of insulinomas include injectable diazoxide (Hyperstat), an insulin-release inhibitor, and, more recently, glucagon delivered by continuous infusion through a portable pump. Both of these agents are used in conjunction with frequent high-carbohydrate meals.

Patients with the glucagonoma syndrome are treated symptomatically with insulin, high-protein meals, supplemental zinc, amino acid infusions, and anticoagulants.

Bisphosphonate therapy should be considered for patients with bone metastases.

Hepatic arterial embolization. Hepatic arterial embolization, given with chemotherapy (chemoembolization), 90yttrium microspheres (radioembolization), or without, is an alternative palliative regional therapy for patients with either carcinoid tumors or a PNET who have predominant liver metastases or symptoms. Embolization is best reserved for patients with < 75% tumor involvement of the liver, bilirubin level < 2 mg/dL, and an ECOG performance status of ≤ 2. In addition, a patent main portal vein is required for this procedure.

Other liver-directed therapeutic strategies include radiofrequency ablation (RFA) or cryotherapy for select patients amenable to ablative techniques.

Carcinoid Tumors of the GI Tract

Carcinoid tumors typically arise from components derived from the primitive gut, lungs, and, rarely, the gonads. Approximately 85% of all carcinoids originate from the gut, predominantly the appendix, followed by the small bowel and the rectum.

These tumors have the propensity to cause considerable morbidity by virtue of creating a syndrome of hormonal excess. For example, although the majority of carcinoids are hormonally inert, these neoplasms may produce excessive amounts of serotonin (from dietary tryptophan), prostaglandins, kinins (secondary to kallikrein release), and a variety of other hormones, which may account for the “carcinoid syndrome.” SEER data suggest an increase in the incidence of carcinoid tumors between 1973 and 1990.

Signs and Symptoms

Symptoms of carcinoid tumors are often long-term and vague. The majority of patients diagnosed with carcinoid tumors can have their symptoms (of varying intensity) tracked for 1 year prior.

Flushing

The most common sign of the carcinoid syndrome is flushing, which is often triggered by alcohol, catecholamines, or emotional stress. It ranges in severity from a minor annoyance to profound vasodilatation with near­syncope and hypotension.

Diarrhea

Diarrhea is also common and is due to GI hypermotility. It usually occurs after meals and is rarely voluminous, bulky, or foul-smelling.

Abdominal cramps

Diarrhea may be associated with crampy pain, although other etiologies for the pain must be considered, including bowel obstruction due to tumor or mesenteric fibrosis.

Bronchospasm

Patients may also develop bronchospasm, which may be mediated by histamine. This problem is often associated with flushing, although it is less common.

Cardiac disease

A late finding is right-sided valvular heart disease, although left-sided lesions may be noted occasionally. The fibrous deposits may lead to tricuspid insufficiency and/or pulmonary stenosis. Valve replacement is rarely necessary. Because the disease remains undiagnosed in many patients, a cardiac evaluation should be performed in all patients who have carcinoid syndrome.

Symptom triad

If there is sufficient shunting of dietary tryptophan from niacin to serotonin synthesis, patients may present with diarrhea, dermatitis, and dementia. However, this symptom triad is rare if patients maintain adequate intake of a balanced diet.

Diagnosis

Diagnostic studies include CT/MRI of the abdomen and a 24-hour urine test for 5-hydroxyindoleacetic acid. Some radiologists prefer to obtain a triple-phase CT scan of the liver to detect these highly vascular liver metastases.

Octreotide scanning

111Indium octreotide scintigraphy (OctreoScan) has a higher sensitivity for detecting carcinoid tumors and is superior to CT or MRI for detecting metastatic disease, particularly extrahepatic disease. One study suggests that 111indium octreotide scintigraphy can reduce costs by avoiding unnecessary surgeries. Also, a positive scan may predict which patients may benefit from treatment with somatostatin analogs (eg, octreotide). Initial studies with a new peptide tracer, 111indium 1,4,7,10-tetraazacyclododecane-N,N,N',N'-tetraacetic acid-lanreotide, suggest high tumor uptake and a more favorable dosimetry than is seen with 111indium diethylene triamine pentaacetic acid-d-[Phe1]-octreotide. Other scans of increasing interest include 68Ga-DOTA-1-Nal3-octreotide (68Ga-DOTANOC) and 68Ga-DOTA-D-Phe1-Tyr3-octreotate (68Ga-DOTATATE).

TABLE 3: TNM staging of neuroendocrine tumors

Staging and Prognosis

Staging

Carcinoid tumors are staged according to local spread of disease, nodal status, and distant metastatic involvement, using the AJCC TNM system (Table 3).

The site of tumor origin is potentially prognostic, because most appendiceal carcinoids (75%) are < 1 cm when found and are usually cured by resection. Similarly, rectal carcinoids are usually small and completely resectable for cure.

In contrast, small bowel carcinoids tend to present at a more advanced stage, and approximately one-third have multicentric primary lesions. However, if the disease is completely resectable, patients have a 20-year survival rate of 80%; patients with unresectable intra-abdominal or hepatic metastases have median survival durations of 5 and 3 years, respectively.

• Gastric carcinoids-Types I and II are often multifocal, associated with an elevated gastrin level, and relatively indolent, whereas type III gastric carcinoids are solitary, have a normal gastrin level, and have a more aggressive clinical course.

Treatment

The management of carcinoid tumors focuses not only on treating bulky disease, as with other solid malignancies, but also on treating the complications of hormonal excess.

Treatment of bulky disease

Surgery.

• Appendiceal carcinoids-For tumors that are found incidentally in the appendix and that are probably between 1 and 2 cm, appendectomy is the treatment of choice. For tumors > 2 cm, a right hemicolectomy and lymph node dissection are appropriate.

Small intestines and rectal carcinoids should be resected with a wedge lymphadenectomy to evaluate nodal disease. Small distal rectal tumors (< 2 cm) can undergo local excision via transanal techniques. Duodenal lesions should be locally excised if they are small (< 2 cm), with radical resection reserved for larger tumors.

• Tumor debulking-Liver resection or ablation of liver metastases with cryotherapy or radiofrequency techniques is useful in patients with limited extrahepatic disease and/or symptomatic carcinoid syndrome. Tumor debulking can protect liver functional reserve and improve quality of life.

• Liver transplantation-Liver transplantation may be of benefit in highly select patients without extrahepatic disease whose cancer progresses after other therapeutic interventions.

Preoperative and intraoperative considerations. All patients with metastatic, hormonally active carcinoid tumors require echocardiograms before any surgical intervention to evaluate for valvular disease. Furthermore, patients will require preoperative treatment with octreotide either subcutaneously or intravenously. Administration of intravenous octreotide is the preferred method of managing carcinoid crisis. All patients undergoing operative intervention should have a cholecystectomy, because octreotide use can promote the development of gallstones. Also, regional therapy for the liver with the use of embolic material, can cause acute cholecystitis.

Radiation. Carcinoid tumors are modestly responsive to radiation therapy and frequently are palliated with this modality. Overall, treatment with higher radiation doses (29–52 Gy) has been associated with higher response rates (40%–50%) than has treatment with lower doses (10%).

A single-arm study (Bushnell JL Jr. et al: J Clin Oncol 2010) of 90yttrium-edotreotide administered to 90 symptomatic patients with carcinoid tumor refractory to octreotide resulted in stable disease or response for 74% of patients.

Chemotherapy. Since carcinoid tumors tend to be resistant to most chemotherapeutic agents, there are no standard regimens for the treatment of unresectable tumors.

• Single agents-Agents that have reported activity include 5-FU, doxorubicin, and recombinant human interferon alfa-2a and alfa-2b. However, the response rate with these agents is in the range of 10% to 20%, the response duration is < 6 months, and complete remission is rare.

• Combination regimens-Combination chemotherapy regimens represent little improvement over single-agent therapy, with response rates ranging from 25% to 35%, response durations < 9 months, and rare complete remissions.

• New agents-Antiangiogenic approaches and the recognition of other potential biologic targets have contributed to the development of a number of early-phase clinical trials incorporating bevacizumab with temozolomide and with FOLFOX chemotherapy, temozolomide and capecitabine, sunitinib (Sutent), sorafenib (Nexavar), vatalanib, imatinib, thalidomide, temsirolimus, and everolimus. Phase III trials are planned or ongoing to further evaluate sunitinib and everolimus. The SWOG-coordinated Intergroup randomized phase III trial comparing depot octreotide (Sandostatin LAR) plus interferon alfa-2b vs depot octreotide plus bevacizumab in advanced carcinoid patients with poor prognosis, showed no difference in a preliminary report.

Management of poorly differentiated (high-grade or anaplastic) neuroendocrine tumors and metastatic disease and postresection therapy for isolated resectable disease consists of the same systemic treatment as that used for small-cell lung cancer. A USA GI Intergroup trial is exploring the use of temozolomide and capecitabine.

Treatment of symptoms

Somatostatin analogs.

• Octreotide-The most active agent is the somatostatin analog octreotide. Even though native somatostatin is effective in controlling many symptoms, due to its short half-life (< 2 minutes), this agent would have to be administered via continuous infusion to be clinically useful. However, octreotide may be administered subcutaneously every 8 to 12 hours, facilitating outpatient therapy. The initial dose of octreotide is 100 to 600 µg/d in two to four divided doses, although the effective dose varies between patients and must be titrated to the individual patient’s symptoms. The most commonly used dose and schedule of somatostatin in the depot formulation is given at monthly doses of 20 mg or higher.

Octreotide not only is useful in managing the chronic problems of the carcinoid syndrome, but it also is effective in treating carcinoid crisis (volume-resistant hypotension), which may be precipitated by surgery or effective antitumor treatment.

Octreotide is well tolerated, although chronic treatment may be associated with cholelithiasis, increased fecal fat excretion, fluid retention, nausea, and glucose intolerance. Occasional objective antitumor responses have been observed in patients who have received octreotide; the median duration of symptomatic improvement is 1 year. A prospective randomized trial in patients with midgut carcinoid tumors compared somatostatin depot (30 mg/monthly) with placebo and reported a significant improvement in progression-free survival, 14 months as compared to 6 months, respectively. Other somatostatin analogs, including lanreotide, pasireotide and vapreotide, are under investigation. A sustained-release formulation of lanreotide (Somatuline Depot) is specifically indicated for the long-term treatment of patients with acromegaly who have responded inadequately to surgery and/or radiotherapy or for whom surgery and/or radiotherapy is not an option. The recently reported CLARINET study for patients with well or moderated differentiated (Ki-67 < 10%) nonfunctioning neuroendocrine tumors who were randomized to receive lanreotide Autogel at 120 mg or placebo every 4 weeks for 96 weeks demonstrated significant improvement in progression-free survival favoring lanreotide. The FDA recently approved lanreotide for the treatment of patients with unresectable, well differentiated or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.

Patients who demonstrate disease resistance with somatostatin analog treatment alone may benefit from combination therapy with interferon-alfa and this somatostatin analog.

• Radiolabeled somatostatin analogs-A promising experimental treatment approach involves the use of octreotide or other somatostatin analogs conjugated to radioisotopes (eg, 111indium or 90yttrium or 177lutetium) in patients whose tumors express somatostatin receptors (eg, those with a positive OctreoScan result). This approach allows targeted in situ radiotherapy by taking advantage of internalization of the radioligand into the cell to produce DNA damage and cell death, with little effect on normal tissue. Initial reports have shown favorable results with this technique. A randomized study of 177lutetium DOTATATE (DOTA-octreotate) vs octreotide at 60 mg (NETTER-1) recently completed accrual, and was presented at the 2016 Gastrointestinal Symposium. A total of 230 patients with low-grade progressive mid-gut neuroendocrine tumors were randomized. Patients randomized to 177lutetium DOTATATE had a higher response rate (18% vs 3% for patients randomized to octreotide; P = .0008). The primary endpoint was progression-free survival, which also favored the 177lutetium DOTATATE group. However, median progression-free survival has not yet been reached for 177lutetium DOTATATE (estimated 40 months vs 8 months; 79% reduction in radiographic progression or death by 79% [HR = 0.21, P < .0001]. Preliminary survival data demonstrated fewer deaths in the 177lutetium DOTATATE group (13 vs 22 deaths). The FDA is currently reviewing the trial data for registration purposes.

Other agents. Other agents that have been used for symptomatic management include histamine type 1 (H1)- and H2-receptor antagonists, methoxamine (Vasoxyl), cyproheptadine, and diphenoxylate with atropine. The symptom complex of diarrhea, dermatitis, and dementia may be prevented or treated with supplemental niacin.

Bisphosphonate therapy should be considered for patients with bone metastases.

Hepatic arterial embolization. Hepatic arterial embolization with such products as Ivalon or Gelfoam, with or without chemotherapy (chemoembolization), is an option for patients with either a carcinoid tumor or an islet-cell carcinoma who have predominant liver metastases or who are symptomatic. These lesions often are hypervascular, and, thus, peripheral hepatic embolization may provide symptomatic relief in some patients. It is unclear whether this therapy has any effect on patient survival.

Other liver-directed therapeutic strategies include RFA for select patients and 90yttrium microspheres.

Adrenocortical Carcinoma

Adrenocortical carcinoma is a rare, highly malignant neoplasm that accounts for about 0.2% of cancer deaths. Long-term survival is poor overall; the survival rate is 23% at 5 years and 10% at 10 years.

Etiology

The etiology of adrenocortical cancer is unknown, but some cases have occurred in families with a hereditary cancer syndrome (eg, multiple neoplasia type I, Li-Fraumeni syndrome, Lynch syndrome or Beckwith-Wiedemann syndrome).

Signs and Symptoms

Approximately half of adrenocortical neoplasms produce hormonal and metabolic syndromes of hormone hypersecretion (such as Cushing syndrome, virilizing or feminizing syndromes, and hyperaldosteronism). In children, Cushing syndrome is rare but is often due to adrenal carcinoma. Mixed syndromes, such as Cushing syndrome and virilization, strongly suggest adrenal carcinoma. The combination of hirsutism, acne, amenorrhea, and rapidly progressing Cushing syndrome in a young female is a typical presentation. In men, estrogen-secreting tumors are associated with gynecomastia, breast tenderness, testicular atrophy, impotence, and decreased libido.

Often, the diagnosis of adrenocortical carcinoma is not evident until the discovery of metastases or until the primary tumor becomes large enough to produce abdominal symptoms. Smaller tumors may be discovered incidentally, when unrelated abdominal complaints are investigated radiographically.

Staging and Treatment

Adrenal gland tumors are staged according to local spread of disease, nodal status, and distant metastatic involvement, using the AJCC TNM system (Table 4).

TABLE 4: TNM staging of adrenal gland tumors

Surgery

Complete surgical resection is the treatment of choice in patients with localized disease, because it offers the best chance of extending the disease-free interval and survival.

Although laparoscopic adrenalectomy is often utilized for adenomas, its role in the management of adrenocortical cancer is controversial. Recent data have shown worse outcomes following laparoscopic resections, compared with open resections. Any disruption of the tumor capsule can lead to peritoneal dissemination; therefore, the open technique is often used.

Following resection, the role of adjuvant therapy is unknown, with no prospective data available. A retrospective study suggests that adjuvant treatment with mitotane (Lysodren) improves recurrence-free survival. Owing to the study methodology, however, the conclusions are not universally accepted. The randomized phase III ADIUVO trial is currently prospectively assessing the role of adjuvant mitotane.

Medical therapy

Mitotane. This drug is one of only a few effective agents; it exerts a specific cytolytic effect on adrenocortical cells and has been used to treat unresectable or metastatic adrenocortical carcinoma. Only 15% to 30% of patients experience objective tumor regression, with a median duration of about 7 months. Mitotane is given at a dose of 4 to 8 g/day as tolerated, although the dosage is variable.

Chemotherapy. Limited studies of combination chemotherapy regimens, including cisplatin/etoposide/mitotane, cisplatin/etoposide/doxorubicin/mitotane, and streptozocin/mitotane, have demonstrated responses of between 35% and 50%. A randomized trial of 304 patients with advanced adrenocortical carcinoma compared mitotane with etoposide, doxorubicin, and cisplatin vs mitotane and streptozocin. There was no difference in survival; however, the three-drug combination produced superior response (23.2% vs 9.2%, P < .001) and progression-free survival (5 months vs 2.1 months, P < .001). The preferred treatment approach remains participation in a clinical trial, when available.

Controlling hormone hypersecretion. Hormone hypersecretion can be controlled medically, in most cases. Agents that are effective in reducing steroid production and in palliating associated clinical syndromes include the antifungal drug ketoconazole, 800 mg/day; aminoglutethimide (Cytadren), 1 to 2 g/day; and metyrapone (Metopirone), 1 to 4 g/day or higher as needed to control cortisol levels. These agents may be used alone or with mitotane.

Pheochromocytomas

Pheochromocytomas are catecholamine-secreting tumors that arise from chromaffin cells in the adrenal medulla or extra-adrenal sympathetic ganglia. These tumors constitute a surgically correctable cause of hypertension in 0.1% to 1% of hypertensive persons.

Only about 10% of pheochromocytomas are considered to be malignant. The vast majority (90%) of pheochromocytomas are found in the adrenal medulla, and 97% are located below the diaphragm. Approximately 10% of pheochromocytomas are either bilateral, malignant, multifocal, extra-adrenal, found in children, or associated with a familial syndrome.

Pheochromocytomas in patients with familial syndromes, such as MEN-2 and von Hippel-Lindau syndrome, are less likely to be malignant than are other adrenal lesions. In contrast, pheochromocytomas in patients with a family history of malignant pheochromocytoma are more apt to be malignant.

In early 2015, Fishbein et al reprorted the association between a somatic mutation in the ATRX gene and malignant pheochromocytomas and paragangliomas.

Epidemiology and Etiology

Pheochromocytomas occur in all age groups, but the incidence peaks in the third to fifth decades of life. Most pheochromocytomas (90%) are sporadic. Approximately 10% of cases are inherited as an autosomal-dominant trait, either independently or as a part of the MEN-2 syndrome; bilateral tumors are more common in this setting.

Both MEN-2A and MEN-2B include medullary thyroid carcinoma and pheochromocytoma. MEN-2A includes hyperparathyroidism, whereas MEN-2B includes ganglioneuromas and marfanoid habitus. In MEN-2 families, pheochromocytoma occurs in 5.5% to 100% (mean, 40%), depending on the kindred studied. Bilateral medullary hyperplasia is almost always present. Pheochromocytomas are bilateral in 70% of cases and usually multicentric, but they are rarely extra-adrenal or malignant. Genetic testing is recommended for patients suspected of having MEN-2.

Signs and Symptoms

Patients can present with various symptoms, ranging from mild labile hypertension to hypertensive crisis, myocardial infarction, or cerebral vascular accident, most of which can result in sudden death. The classic pattern of paroxysmal hypertension occurs in 30% to 50% of cases; sustained hypertension may also occur and resembles essential hypertension. A characteristic presentation includes “spells” of paroxysmal headaches, pallor or flushing, tremors, apprehension, palpitations, hypertension, and diaphoresis.

Diagnosis

The diagnosis of pheochromocytoma relies on an appropriate history and documentation of excessive catecholamine production.

Catecholamine measurements

Measurement of 24-hour urinary catecholamines and their metabolites, vanillylmandelic acid and metanephrine, is commonly done; the metanephrine level is considered to be the most specific single test. Serum catecholamine measurements are more susceptible to false elevations due to stress-related physiologic fluctuations. The evaluation of serum catecholamines after clonidine suppression, however, provides a useful diagnostic tool that is more convenient than urine collection. Dynamic provocative tests are rarely indicated. Recently, the measurement of plasma-free metanephrines has been shown to be an excellent test for excluding or confirming pheochromocytoma.

Radiologic studies

Almost all pheochromocytomas are localized in the abdomen, mostly in the adrenal medulla; other locations include the posterior mediastinum or any distribution of the sympathetic ganglia. After the diagnosis is established biochemically, radiologic methods may be needed for preoperative localization of the lesion; CT and MRI are most widely used. A 131iodine-metaiodobenzylguanidine (MIBG) scan and somatostatin receptor scintigraphy (SRS) provide “functional” images; they are most helpful in the detection of occult contralateral or extra-adrenal lesions.

Differentiating benign from malignant tumors

The histologic differentiation between benign and malignant lesions is extremely difficult and often impossible to make; this distinction may require the development of lymph node, hepatic, bone, or other distant metastases. Recurrent symptoms of pheochromocytoma, often emerging many years after the original diagnosis, are suggestive of malignancy. Biochemical confirmation of recurrent catecholamine hypersecretion and localization of metastatic lesion(s) with 131iodine-MIBG scan constitute diagnostic proof.

Treatment

Preoperative medical management

Phenoxybenzamine (Dibenzyline), an oral, long-acting, noncompetitive alpha-adrenoceptor blocker, is a helpful, widely used first drug; it is given at a dose of 10–40 mg/day. Propranolol, a beta-blocker (20–80 mg/day), is usually added after a few days to prevent tachycardia or arrhythmia. The use of beta-blockers alone is hazardous, because it may precipitate a paradoxical rise in blood pressure. The tyrosine hydroxylase inhibitor metyrosine (Demser) may be added in patients whose blood pressure is not well controlled with the combination of an alpha-blocker and a beta-blocker.

Surgery

The principles of pheochromocytoma resection are complete tumor resection, avoidance of tumor seeding, and minimal tumor manipulation. Adrenalectomy can be performed by means of an open anterior transabdominal, open posterior retroperitoneal, laparoscopic lateral transabdominal, or laparoscopic posterior retroperitoneal approach. In the past, an open anterior approach was the standard, because it allowed for complete exploration and inspection of potential tumor foci. However, with the improved accuracy of preoperative imaging and increased experience with laparoscopic procedures, there is little need for exploration in areas in which a tumor has not been identified.

Except in tumors > 6 cm, the laparoscopic approach to pheochromocytoma is probably the technique of choice. In the absence of obvious local tumor invasion or metastatic disease, a laparoscopic procedure is acceptable to many experienced endocrine surgeons.

The most critical intraoperative aspect of surgery is control of blood pressure immediately after removal of the tumor, when all agonistic effects are abolished and the effects of alpha- and beta-blockers are still present. Close cooperation with the anesthesiologist to expand fluid volume and prepare the appropriate infusions of agonists to support vascular stability is critical.

Treatment of metastatic malignant pheochromocytoma

The treatment of choice for metastatic malignant pheochromocytoma remains problematic.

Medical and radiation therapy. Medical therapy with alpha- or beta-blockers, as well as metyrosine, is almost always required to maintain hemodynamic stability. Chemotherapy using streptozocin-based regimens or the combination of cyclophosphamide, vincristine, and dacarbazine has yielded promising responses. Treatment with 131iodine-MIBG or with radiolabeled somatostatin (in Europe) has met with only limited success; however, clinical trials continue to investigate these approaches. In most cases, uncontrolled catecholamine hypersecretion eventually escapes biochemical blockade and fatal hypertensive crises ensue.

Surgery. In cases in which limited and resectable lesions can be identified, surgery can effect complete and lasting remission of the disease.

Suggested Reading

On Pancreatic Cancer

Abrams MJ, Rakszawski K, Vasekar M, et al: Recent advances in pancreatic cancer: Updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology. Therapy Adv Gastroenterol 9:141151, 2016. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4749860/. Accessed April 17, 2016.

Abrams RA, Winter KA, Regine WF, et al: Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704: A phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 82:809–816, 2012.

Altwegg R, Ychou M, Guillaumon V, et al: Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastoenterol 18:1357–1364, 2012.

Andriulli A, Festa V, Botteri E, et al: Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 19:1644–1662, 2012.

Aschebrook-Kilfoy B, Cross AJ, Stolzenberg-Solomon RZ, et al: Pancreatic cancer and exposure to dietary nitrate and nitrite in the NIH-AARP Diet and Health Study. Am J Epidemiol 174:305–315, 2011.

Bickenbach KA, Gonen M, Tang LH, et al: Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Ann Surg Oncol 19:1663–1669, 2012.

Bilici A: Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J Gastroenterol. 20:10802–10812, 2014.

Bosetti C, Rosato V, Li D, et al: Diabetes, antidiabetic medications, and pancreatic cancer risk: An analysis from the International Pancreatic Cancer Case-Control Consortium. Ann Oncol 25:2065–2072, 2014.

Canto MI, Harinck F, Hruban RH, et al: International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62:339–347, 2013.

Ciliberto D, Botta C, Correale P, et al: Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials. Eur J Cancer 49:593–603, 2013.

Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825, 2011.

Costello E, Greenhalf W, Neoptolemos JP: New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol 9:435–444, 2012.

Dores GM, Curtis RE, van Leeuwen FE, et al: Pancreatic cancer risk after treatment of Hodgkin Lymphoma. Ann Oncol. 25:2073–2079, 2014.

European Society for Medical Oncology: ESMO @ ECC 2015: Progression-free survival prolonged with everolimus in patients with advanced lung/gastrointestinal neuroendocrine tumours [newsbrief]. September 27, 2015. Available from: http://www.esmo.org/Conferences/Past-Conferences/European-Cancer-Congress-2015/News/Progression-Free-Survival-Prolonged-with-Everolimus-in-Patients-with-Advanced-Lung-Gastrointestinal-Neuroendocrine-Tumours. Accessed March 16, 2016.

Golan T, Kaji KS, Epelbaum R, et al: Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111:1132–1138, 2014.

Heinrich S, Pestalozzi B, Lesurtel M, et al: Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: A randomized multicenter phase III study (NEOPAC study). BMC Cancer 11:346, 2011.

Katz MH, Varadhachary GR, Fleming JB, et al: Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 17:1794–1801, 2010.

Loehrer PJ Sr, Feng Y, Cardenes H, et al: Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial. J Clin Oncol 29:4105–4112, 2011.

Neoptolemos JP, Moore MJ, Cox TF, et al: Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: The ESPAC-3 periampullary cancer randomized trial. JAMA 308:147–156, 2012.

Neoptolemos JP, Stocken DD, Bassi C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA 304:1073–1081, 2010.

Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297:267–277, 2007.

O’Reilly EM: Evolving panorama of treatment for metastatic pancreas adenocarcinoma. J Clin Oncol 31:1621–1623, 2013.

Philip PA, Mooney M, Jaffe D, et al: Consensus report of the National Cancer Institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 27:5660–5669, 2009.

Regine WF, Winter KA, Abrams R, et al: Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 18:1319–1326, 2011.

Stenger M: Prime-boost vaccine increases survival in metastatic pancreas cancer. ASCO Evening Post 5:20, 2014.

Tempero MA, Malafa MP, Behrman SW, et al: Pancreatic adenocarcinoma. v2.2014. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 12:1083–1093, 2014.

Von Hoff DD, Ervin T, Arena FP, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703, 2013.

Wong GY, Schroeder DR, Carns PE, et al: Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: A randomized controlled trial. JAMA 3:1092–1099, 2004.

Yuan C, Rubinson DA, Qian ZR, et al: Survival among patients with pancreatic cancer and long standing or recent-onset diabetes mellitus. J Clin Oncol 33:29–35, 2014.

On Pancreatic Cystic Neoplasms

Jana T, Schroff J, Bhutani MS, et al: Pancreatic cystic neoplasms: Review of current knowledge, diagnostic challenges, and management options. J Carcinog 2015 Mar 14 [eCollection 2015]

Tanaka M, Fernández-del Castillo C, Adsay V, et al; International Association of Pancreatology: International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12:183–197, 2012.

Vege SS, Ziring B, Jain R, et al, and the Clinical Guidelines Committee: American Gastroenterological Association Institute guideline on the diagnosis and management of asymptomatic neoplastic pancreacytic cysts. Gastroenterology 148:819–822, 2015. Available from: http://www.gastrojournal.org/article/S0016-5085%2815%2900100-6/pdf. Accessed on April 17, 2016.

On Neuroendocrine GI Tumors

Bondwoman JB, Passionateness ND:111In-DTPA0-octreotide (Stereoscope), 131I-MIBG and other agents for radionuclide therapy of Nets. Eur J Null Med Mil Imaging 39(Suppl):S113–S125, 2012.

Chan JA, Stuart K, Earle CC, et AL: Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 30:2963–2968, 2012.

Hsu C, Rashid A, Xing Y, et al: Varying malignant potential of appendiceal neuroendocrine tumors: Importance of histologic subtype. J Surg Oncol 107:136–143, 2013.

Imhof A, Brunner P, Marincek N, et al: Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 29:2416–2423, 2011.

Ito T, Igarashi H, Uehara H, et al: Causes of death and prognostic factors in multiple endocrine neoplasia type 1: A prospective study: Comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 92:135–181, 2013.

Johnston FM, Mavros MN, Herman JM, et al: Local therapies for hepatic metastases. J Natl Compr Canc Netw 11:153–160, 2013.

Klimstra DS: Pathology reporting of neuroendocrine tumors: Essential elements for accurate diagnosis, classification, and staging. Semin Oncol 40:23–36, 2013.

Kulke MH: Are neuroendocrine tumors going mainstream? J Clin Oncol 31;404–405, 2013.

Kulke MH, Shah MH, Benson AB 3rd, et al: Neuroendocrine tumors. v1.2015. J Natl Compr Canc Netw 13:78–108, 2015.

Kulke MH, Siu LL, Tepper JE, et al: Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29:934–943, 2011.

Kvols L, Oberg KE, O’Dorisio T, et al: Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: Results from a phase II study. Endocr Relat Cancer 19:657–666, 2012.

Le Truet YP, Gregoire E, Klempnauer J, et al: Liver Transplantation for neuroendocrine tumors in Europe–results and trends in patient selection: A 213-case European liver transplant registry study. Ann Surg 257:807–815, 2013.

Moline J, Eng C: Multiple Endocrine Neoplasia Type 2: GeneReviews at Gene Tests: Medical Genetics Information Resource (database online). 1997–2013. Copyright 2013, University of Washington, Seattle. Accessed April 16, 2013.

Qian ZR, Ter-Minassian M, Chan JA, et al: Prognostic significance of MTOR pathway component expression in neuroendocrine tumors. J Clin Oncol 31;3418–3425, 2013.

Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513, 2011.

Ruszniewski P, Caplin M: A randomized, double-blind, placebo-controlled study of lanreotide antiproliferative response in patients with gastroenteropancreatic neuroendocrine tumors (CLARINET) [abstract]. 17th ECCO – 38th ESMO – 32nd ESTRO European Cancer Congress 2013. Abstract E17-7103.

Saxena A, Chua TC, Perera M, et al: Surgical resection of hepatic metastases from neuroendocrine neoplasms: A systematic review. Surg Oncol 21:e131–e141, 2012.

Strosberg JR, Cheema A, Weber JM, et al: Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: An analysis of the AJCC and ENETS staging classifications. Ann Surg 256:321–325, 2012.

Tsikitis VL, Wertheim BC, Guerrero MA: Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: A SEER analysis. J Cancer 3:292–302, 2012.

Villard L, Romer A, Marincek N, et al: Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA-TOC] plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 30:1100–1106, 2012.

On Adrenal Neoplasms

Aktolun C, Castellani MR, Bombardieri E: Diagnostic and therapeutic use of MIBG in pheochromocytoma and paraganglioma. Q J Nucl Med Mol Imaging 57:109–111, 2013.

Dreicer R: Systemic therapy for advanced adrenal cancer. J Surg Oncol 106:643–646, 2012.

Fassnacht M, Terzolo M, Allolio B, et al: Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366:2189–2197, 2012.

Lehmann T, Wrzesinski T: The molecular basis of adrenocortical cancer. Cancer Genet 205:131–137, 2012.

Libè R, Fratticci A, Bertherat J: Adrenocortical cancer: Pathophysiology and clinical management. Endocr Relat Cancer 14:13–28, 2007.

Milgrom SA, Goodman KA: The role of radiation therapy in the management of adrenal carcinoma and adrenal metastases. J Surg Oncol 106:647–650, 2012.

Parenti G, Zampetti B, Rapizzi E, et al: Clinical relevance of phenotype/genotype correlations in the diagnosis and therapy of pheochromocytomas/paragangliomas. Q J Nucl Med Mol Imaging 57:112–121, 2013.

Pua BB, Solomon SB: Ablative therapies in adrenal tumors: Primary and metastatic. J Surg Oncol 106:626–631, 2012.

Raymond VM, Everett JN, Furtado LV, et al: Adrenocortical carcinoma is a lynch syndrome-associated cancer. J Clin Oncol 31;3012–3018, 2013.

Terzolo M, Angeli A, Fassnacht M, et al: Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356:2372–2380, 2007.

On Carcinoids

Arnold R, Wittenberg M, Rinke A, et al: Placebo controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the controlled tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results on long-term survival. J Clin Oncol 31(suppl): Abstract 4030, 2013.

Bhattacharyya S, Toumpanakis C, Chikunda D, et al: Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol 107:1221–1226, 2011.

Bushnell DL Jr, O’Dorisio TM, O’Dorisio MS, et al: 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28:1652–1659, 2010.

Kim MK, Warner RR, Roayaie S, et al: Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors. J Clin Oncol 31:3776–3781, 2013.

Kolby L, Persson G, Franzen S, et al: Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 90:687–693, 2003.

Moller JE, Connolly HM, Rubin J, et al: Factors associated with progression of carcinoid heart disease. N Engl J Med 348:1005–1015, 2003.

Paulson AS, Bergsland EK: Systemic therapy for advanced carcinoid tumors: Where do we go from here? J Natl Compr Canc Netw 10:785–793, 2012.

Rinke A, Muller HH, Schade-Brittinger C, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 27:4656–4663, 2009.

Sharpiro R, Eldar S, Sadot E, et al: Appendiceal carcinoid at a large tertiary center: Pathologic findings and long-term follow-up evaluation. Am J Surg 201:805–808, 2011.

Strosberg JR, Weber JM, Feldman M, et al: Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol 31:420–425, 2013.

van der Horst-Schrivers AN, Wymenga AN, de Vries EG: Carcinoid heart disease. N Engl J Med 348:2359–2361, 2003.

On Pheochromocytomas

Burnichon N, Cascon A, Schiavi F, et al: MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 18:2828–2837, 2012.

Chen H, Sippel R, O’Dorisio MS, et al: The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39:775–783, 2010.

Fishbein L, Khare S, Wubbenhorst B, et al: Whole exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun 6:6140, 2015.

Safford SD, Coleman RE, Gockerman JP, et al: Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134:956–962, 2003.